Study did not meet primary endpoint in change from baseline in mean daily oral corticosteroid (OCS) dose at week 48, although clinical benefit for efzofitimod observed across multiple study parameters. 52.6% of patients treated with 5.0 mg/kg efzofitimod achieved complete steroid withdrawal at week 48 vs 40.2% on placebo (p=0.0919). Clinical improvement in King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week …
Read More »Tag Archives: aTyr
aTyr Pharma’s Phase 3 Sarcoidosis Drug Misses Primary Endpoint
aTyr Pharma (Nasdaq: ATYR) announced topline results from its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. The study did not meet its primary endpoint of change in mean daily oral corticosteroid dose at week 48, with a reduction to 2.79 mg for efzofitimod vs 3.52 mg for placebo (p=0.3313). However, …
Read More »